CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net income	$ 52,046	$ 137,230
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	51,295	36,605
Amortization of debt issuance costs	1,373	1,360
Stock-based compensation	19,110	21,054
Deferred income taxes, net	(9,268)	1,722
Contingent consideration	(31,266)	(11,604)
Non-cash interest income	(2,023)	0
Operating lease right of use asset amortization*	10,203	5,672
Other	1,275	210
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	8,315	(8,609)
Inventories	25,979	(64,308)
Prepaid expenses and other assets	(12,749)	168
Other assets	(707)	(298)
Accounts payable	(8,619)	(10,124)
Accrued expenses	(12,514)	3,043
Operating lease Liabilities	(7,676)	(1,548)
Long-term liabilities	79	(372)
Total cash provided by operating activities	84,853	110,201
Cash flows from investing activities:
Acquisitions, net of cash acquired	(27,843)	0
Proceeds from maturity of marketable securities held to maturity	102,323	0
Additions to capitalized software costs	(2,736)	(2,568)
Purchases of property, plant and equipment	(25,135)	(64,390)
Purchase of intellectual property	0	(45,000)
Other investing activities	21	30
Total cash provided by (used in) investing activities	46,630	(111,928)
Cash flows from financing activities:
Proceeds from exercise of stock options	356	2,784
Payment of tax withholding obligation on vesting of restricted stock	(12,178)	(15,829)
Repayment of Convertible Senior Notes	(33)	(18)
Payment of earnout consideration	(7,298)	0
Proceeds from issuance of common stock, net	(13)	0
Total cash used in financing activities	(19,166)	(13,063)
Effect of exchange rate changes on cash and cash equivalents	(4,996)	(15,661)
Net increase (decrease) in cash and cash equivalents	107,321	(30,451)
Cash, cash equivalents and restricted cash, beginning of period	523,458	603,814
Cash and cash equivalents, end of period	630,779	573,363
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	1,129	25,705
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.	5,465	0
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of contingent consideration earnouts related to acquisition	$ 7,229	$ 0